Navigating the complexities of bringing new drug therapies to market in Europe is a formidable challenge, especially with the diverse and fragmented reimbursement landscape across the EU’s 27 member states. In this insightful article published in European Biopharmaceutical Review, EVERSANA’s Mike Ryan and Paolo Correale delve into the intricacies of the European market access process, highlighting the significant hurdles pharmaceutical and life sciences brands face. From the prolonged timelines for Health Technology Assessments (HTAs) to the disparities in access between wealthier and less affluent nations, the authors provide a comprehensive overview of the current landscape and its impact on patient access to innovative treatments.
The article also explores emerging solutions aimed at improving market access and health equity across Europe. Key initiatives such as the harmonization of HTA processes, the implementation of Risk-Sharing Agreements (RSAs), and the focus on data integration are discussed in detail. Additionally, the authors emphasize the need for better access to rare and orphan disease products and the importance of addressing International Reference Pricing (IRP) challenges. By adopting these strategies, the industry can work towards a more equitable and efficient market access framework, ultimately benefiting millions of patients across the region.
Read the full article here to gain deeper insights into these critical issues and discover how EVERSANA is leading the charge in transforming market access in Europe.
Author
With more than 25 years of experience in the life sciences industry, Mike has held global leadership positions in both clinical development and life sciences software companies. Given this experience, he is highly experienced…
Paolo leads EVERSANA’s Global Pricing & Access Consulting team thanks to an experience of 15 years as a management consultant in the life sciences industry. He specializes in pricing and market access and has…